LexaGene Adopts Corporate Governance Charters and Policies
September 17 2021 - 4:00PM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)
(“LexaGene” or the “Company”), a commercial molecular diagnostics
company selling a point-of-need highly multiplexed in-clinic PCR
system with results in approximately two hours, today announced the
Company has adopted new corporate governance charters and policies.
Dr. Jack Regan, LexaGene’s CEO and Founder stated, “The Board of
Directors, along with our leadership team, take good corporate
governance seriously. The Board reviewed our existing charters and
policies and felt it was time to modernize them. By doing so, we
are elevating our effectiveness and moving in a direction where
accountability, the ability to manage resources, and improving our
performance strengthen strategic business imperatives.”
The Board of Directors adopted a new audit committee charter, a
compensation committee charter, a nominating and corporate
governance charter, a cyber security policy, and a code of business
conduct and ethics. These charters and policies are available on
our website or by contacting info@lexagene.com.
The Board also announced that it has filed and
obtained receipt for, a final base shelf prospectus (the “Shelf
Prospectus”) allowing the Company to offer up to $25,000,000 of
common shares, warrants, subscription receipts, debt securities or
units or any combination thereof (collectively, the “Securities”),
from time to time during the 25-month period that the Shelf
Prospectus is effective. LexaGene filed the Shelf Prospectus with
the securities commissions in all the provinces and territories of
Canada (the “Qualifying Jurisdictions”). The specific terms of any
future offering of Securities will be set forth in a prospectus
supplement to the Shelf Prospectus, which will be filed with the
applicable securities’ regulatory authorities in connection with
any such offering. A copy of the Shelf Prospectus can be found on
SEDAR at www.sedar.com.
The Securities have not been, nor will they be, registered under
the United States Securities Act of 1933, as amended, and may not
be offered or sold within the United States or to, or for the
account or benefit of, U.S. persons absent U.S. registration or an
applicable exemption from the U.S. registration requirements. This
news release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these Securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such
jurisdiction.
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
Corporate Contact:Gail WinslowDirector of
Marketinggwinslow@lexagene.com978.482.6237
ir@lexagene.com800.215.1824
Media:Shani LewisAccount
ManagerLavoieHealthScienceslewis@lavioehealthscience.com609-516-5761
Investors:Sharon ChoeVice
PresidentLaVoieHealthScienceschoe@lavoiehealthscience.com(857)
241-7393
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing, and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024